News »Agilvax Receives Notice of Allowance for U.S. and European Patents Covering its Vaccine and Cancer Immunotherapy Discovery and Development Platform Technology


Albuquerque, NM

February 29th, 2016

Agilvax, Inc. (www.agilvax.com) is pleased to announce that it has recently received a Notice of Allowance in United States Patent Application serial number 13/520,057 and an Intention to Grant in European Patent Application 10841780.9 entitled, “Plasmids and Methods for Peptide Display and Affinity-Selection on Virus-Like Particles of RNA Bacteriophages”. This platform has produced multiple cancer immunotherapies and vaccines, which are undergoing evaluation in preclinical studies.

“This unique virus-like particle (VLP) library and affinity selection process is a first-in class technology and we are pleased that the United States Patent and Trademark Office recognizes the novelty, utility and application of this platform” commented Federica Pericle, PhD, MBA, President and Chief Executive Officer of Agilvax. “We knew of the power of the technology platform and being awarded these patents is the ultimate validation and we are excited to progress our lead candidates.

Agilvax’s intellectual property portfolio related to VLPs contains these soon to be issued patents and nine pending patent applications in several countries across the globe. These patents and patent applications cover composition of matter and methods of use.

About Agilvax

Agilvax (www.agilvax.com) is a biotechnology company that is developing targeted vaccines and cancer immunotherapies based on a proprietary virus-like particle (VLP) platform technology. The technology integrates epitope identification and immunogenic presentation of epitopes in a single platform. Agilvax is advancing cancer immunotherapies targeting breast and metastatic cancers and vaccines targeting HPV, RSV, malaria and ebola. The Company was founded in 2011 and has headquarters in Albuquerque, NM and an office in El Paso, TX.


Back to News